PMCF Retrospective Study Outcomes of a Premium Monofocal IOL

Cataract Clinical Trial

— PHY2110  

Official title:

Clinical Study to Investigate Visual Performance, Contrast Sensitivity and Patient Satisfaction After Implantation of a Premium Monofocal Intraocular Lens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04874376
• Other study ID #: PHY2110
• Status: Completed
• Phase: N/A
• Start date: May 24, 2021
• Est. completion date: January 12, 2022

Study information

• Verified date: July 2022
• Source: Beaver-Visitec International, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multicentric, retro- / prospective, open-label, observational PMCF study to investigate visual performance, contrast sensitivity and patient satisfaction after mono- or bilateral implantation of Isopure 1.2.3. intraocular lenses following cataract surgery.

The study treatment itself is not part of this observational clinical investigation. Only patients that already have been implanted with the device under investigation qualify for this retro- prospective observational clinical study.

Description:

The study is a multicentric, retro- / prospective, open-label, observational PMCF study to investigate visual performance, contrast sensitivity and patient satisfaction after mono- or bilateral implantation of Isopure 1.2.3. intraocular lenses following cataract surgery.

The study treatment itself is not part of this observational clinical investigation. Only patients that already have been implanted with the device under investigation qualify for this retro- prospective observational clinical study.

Isopure 1.2.3. is CE approved and commercially available in the countries this clinical investgation is being carried out. The investigational device and all study products, including the devices used for the study examinations, will be used within the intended use specifications from the manufacturer. In addition, no invasive or other burdening examinations will occur for the patient.

The study will be carried out in up to five clinical centers in Spain. The device under investigation (Isopure 1.2.3.) is a hydrophobic, glistening-free, acrylic Premium Monofocal intraocular lens (IOL) manufactured by the sponsor of this study, PhysIOL sa/nv.

Subjects participating in the trial will attend a total of maximum 1 study visit (from 120 days post-operative). This study visit will be minimum 20 days after the surgery of the 2nd eye. Subjects would have the option for unscheduled visits if required medically.

The primary performance endpoint is to show that the monocular Best Corrected Distance Visual Acuity (CDVA) measured in the study group is statistically non-inferior to outcomes of the monofocal parent lens Micropure 1.2.3. The comparative data is used from the latest Clinical Evaluation Report (CER) for the monofocal Micropure 1.2.3. lens. To avoid bias, only the first implanted eye will be considered for this calculation. Data interim analyses will be done after the last patient finished the 1 study visit postoperative examination to support the study publication plan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 109
• Est. completion date: January 12, 2022
• Est. primary completion date: January 12, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

• • Male or female adults ages 45 years or older on the day of treatment that were mono- or bilaterally implanted with Isopure 1.2.3. intraocular lens minimum 120 days before the study visit;

• Maximum time between first and second eye treatment: 45 days (this accounts for bilateral implantations only);

• Capability to understand and sign an IRB approved informed consent form and privacy authorization;

• Clear intraocular media;

• Minimum set of retrospective preoperative and intraoperative data available as outlined in the examination matrix;

• Willing and able to conform to the study requirements.

Exclusion Criteria:

• • Age of patient <45 years at the day of surgery;

• Time between first and second eye treatment: >45 days (this accounts for bilateral implantations only);

• Subjects who underwent previous intraocular or corneal surgery other than IOL implantation;

• Subjects with diagnosed degenerative visual disorders (e.g. AMD or CME);

• Subjects in whom in-the-bag implantation was not possible;

• Subjects in whom surgical complications occurred (e.g. posterior rupture).

• Subjects showing glaucoma;

Related Conditions & MeSH terms

• Cataract
• Lens Opacities

Intervention

Device:
• IOL implantation experimental (Isopure 1.2.3.)
Implantation of Premium Monofocal Isopure 12.3 with retrospective data collection

Locations

Country	Name	City	State
Spain	Oftalvist, Alicante	Alicante
Spain	Vithas, Alicante	Alicante
Spain	Clinica Baviera	Madrid
Spain	HM Monteprincipe	Madrid
Spain	HM Vallés	Madrid
Spain	Augenklinik, Palma de Mallorca	Multiple Locations

Sponsors (2)

Lead Sponsor	Collaborator
Beaver-Visitec International, Inc.	targomedGmbH

Country where clinical trial is conducted

Spain, 

References & Publications (1)

Morlock R, Wirth RJ, Tally SR, Garufis C, Heichel CWD. Patient-Reported Spectacle Independence Questionnaire (PRSIQ): Development and Validation. Am J Ophthalmol. 2017 Jun;178:101-114. doi: 10.1016/j.ajo.2017.03.018. Epub 2017 Mar 22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	monocular Best Corrected Distance Visual Acuity (CDVA) under photopic light conditions on the first implanted eye.	No statistically significant difference between the monocular CDVA from 4 months follow up visit when compared to the parent IOL (Micropure 1.2.3). A significance level of 0.025 or lower (p < 0.025) will be considered statistically significant. CDVA is measured with ETDRS charts placed in 4m distance with best aided corrective glasses according to ISO 11979-7:2018.	From 120 days postoperative